Dynavax Restructures and Emphasizes Immuno-Oncology Program
To achieve these savings,
"We value all of our colleagues, so reducing our workforce is a sad and difficult decision. But it is one we believe is necessary to align our organization to reflect that of a clinical R&D-stage company with a promising immuno-oncology pipeline, which has become a strategically important area of our business and one we believe can potentially benefit thousands of people with cancer," said
Prioritizing Diversified Immuno-Oncology Pipeline
The company's lead clinical candidate, SD-101, an investigational cancer immunotherapeutic, is currently being studied in several Phase 1/2 studies evaluating its potential to be broadly effective against multiple solid tumors and hematologic malignancies. SD-101, an intratumoral TLR9 agonist, has shown encouraging early clinical data in metastatic melanoma.
The company expects to present additional data from its immuno-oncology portfolio at medical conferences throughout 2017, including at the
Continuing to Advance HEPLISAV-B while Maintaining Manufacturing Capacity at Reduced Cost
Conference Call Details
DV281, a newly developed TLR9 agonist, is a CpG-C class oligodeoxynucleotide developed specifically for inhaled delivery to lung tumors that are not easily accessible for intratumoral injection. Inhaled DV281 induces dendritic cell activation and tumor microenvironment changes comparable to intratumoral injection of SD-101. Studies in animal models of lung tumors show that DV281 dramatically reduces lung tumor burden and leads to immune-mediated control of tumor metastases outside the lung.
HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with
This press release contains "forward-looking" statements and estimates, including estimated
News Provided by Acquire Media